COMPANY PROFILE

Zurex Pharma

Zurex Pharma, Inc. | Anti-microbial products designed to reduce the risks associated with surgical site infections (SSI) and catheter-related bloodstream infections (CRBSI).

Madison, United StatesFounded 2010Biotech & Life Sciences

Valuation $25–50M Last recorded · 2023

Revenue $1–10M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Zurex Pharma

Zurex Pharma, Inc. operates as a specialty pharmaceutical and medical technology company, strategically focused on mitigating the risks of healthcare-associated infections. Established in 2008 and headquartered in Middleton, Wisconsin, the firm was formed as a subsidiary of Ash Access Technology, Inc. The company is steered by President and CEO Carmine J. Durham, a veteran executive from the specialty pharma sector, including a prior role at BoneCare International. Durham, along with a management team of experienced medical device and pharma professionals, has guided the company's vision and strategy since its formal headquarters launch in Madison in 2010.

The company's core business involves the development and commercialization of an antimicrobial technology platform aimed at preventing surgical site infections (SSIs) and catheter-related bloodstream infections (CRBSIs). This market is substantial, with healthcare-acquired infections representing a significant cost to the healthcare system annually. Zurex Pharma targets hospitals, ambulatory settings, and home care environments, providing solutions for a market with an estimated potential of several hundred million dollars. The firm generates revenue through the sale of its product portfolio, bolstered by significant venture capital funding rounds from investors like Baird Capital and the State of Wisconsin Investment Board.

Zurex Pharma's product pipeline includes several key antimicrobial solutions. ZuraPrep™ is a pre-surgical skin antiseptic designed to decontaminate a surgical area. Its proprietary formula uses small amounts of paraben and citrate to enhance and prolong the antimicrobial effect of its alcohol base, demonstrating favorable results in studies compared to market-leading products. For catheter care, the company has developed ZuraGard™, for preventing infections at the catheter exit site, and ZurAsept™, a catheter lock solution to prevent intra-luminal infections. ZurAsept is positioned to establish a new therapy class, as there are no direct competitors for preventing infections in non-dialysis central lines. The company also has a product for the agricultural market, ZuraLac™, which is a teat sanitizer for dairy cattle.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2010
Headquarters: Madison, United States
Employees: 9
Open positions: None listed
Dealroom signal: 29.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Risk Management, Biotechnology, Surgery, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing, Marketplace & ecommerce
Client focus: b2c
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Dec 2023	$3.8M	$45M	Undisclosed	—
SERIES D✓Equity / VC	Jun 2018	$9M	$36M	Square 1 Bank · Baird Capital · Peak Ridge Capital	—

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Zurex Pharma website traffic

Latest recorded traffic for Zurex Pharma is 720 monthly website visits, up 89.5% over the last three months. Zurex Pharma's team declined 18.2% over the past year.

Latest monthly visits720 3-month web change+89.5% 1-year team growth-18.2%

Monthly website visitsApr 2016–Oct 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CACartivaDeveloper of innovative products for the treatment of cartilage injuries and osteoarthritis	Alpharetta, United States	Acquired	7	$23M	$435M
RSRF Surgical SystemsRF Surgical Systems Inc \| Retained surgical sponge prevention \| OR patient safety \| RFSurg.com	Carlsbad, United States	Acquired
MSMinerva SurgicalDelivering next generation products for the treatment of abnormal uterine bleeding, a condition that affects almost 1 in 5 women	Cupertino, United States	Operational
ZIZirMedWeb-based revenue cycle management solutions for the healthcare business	Louisville, United States	Acquired
VCVenus ConceptVenus Concept is a non-invasive medical aesthetics company	Tel Aviv-Yafo, Israel	Acquired
MSMedical Compression SystemsUp to 5% of patients undergoing #Total #Knee or #Hip #Replacement #surgery suffer a major bleeding complication. Don't be 1 of them! http://t.co/bSgv2waobz	Or Akiva, Israel	Operational
ABArkis BioSciencesMedical device company providing minimally invasive surgical instrumentation and advanced implantable technology	Knoxville, United States	Acquired
ADAdmetsysFor people at diabetic risk, glucose control is at its most crucial while in hospital or surgery	Boston, United States	Operational